Login to Access Video or Poster Abstract: MP89-12
Sources of Funding: None

Introduction

To evaluate the efficacy of pseudoephedrine treatment in patients with retrograde ejaculation._x000D_

Methods

A retrospective analysis was performed of men seen at a infertility clinic treated with pseudoephedrine for retrograde ejaculation between January 2010 and May 2016. All patients had a semen analysis and post-ejaculatory urinalysis before and after treatment. The treatment protocol consisted of 60 mg of pseudoephedrine every 6 hours on the day before semen analysis and two more 60 mg doses on the day of the semen analysis._x000D_

Results

Twenty men were medically treated with pseudoephedrine for retrograde ejaculation between January 2010 and May 2016 (12 with complete retrograde ejaculation and 8 with partial retrograde ejaculation). Diabetes was the most common etiology for complete retrograde ejaculation (60%), while an idiopathic cause was the most common etiology for partial retrograde ejaculation (82%). Of the 12 complete retrograde ejaculation patients treated with pseudoephedrine prior to semen analysis, 7 (58.3%) recovered sperm in the antegrade ejaculate, with a mean total motile count of 54 ± 20 million. Out of the 8 patients with partial retrograde ejaculation, 5 (62.5%) had a ≥ 50% increase in the antegrade total sperm count. The mean total motile count in this group increased from 6.6 ± 3.2 million before treatment to 31.6 ± 13.9 million after treatment, while the percentage of sperm in the urine declined from 41.9 ± 11.2% to 17 ± 10%, respectively (both p < 0.05). Overall, some improvement in seminal parameters occurred in 14 (70%) patients, with 10 patients (38.5% of all patients) achieving antegrade total sperm counts over 39 million._x000D_ _x000D_

Conclusions

In men with retrograde ejaculation, a pseudoephedrine regimen prior to ejaculation confers some improvement in ejaculated semen parameters for approximately two thirds of patients and an ejaculated total motile count of greater than 20 million for approximately one third of patients._x000D_

Funding

None